Basic study on the chemosensitivity test by miniaturized improved nucleic acid precursor incorporation assay (MINi assay)
Mogi, M.; Motohashi, M.; Hirota, T.; Ohshima, K.; Takahashi, N.; Kinoshita, Y.; Tanigawa, M.; Yoshinobu, T.; Koya, Y.; Masutani, M.
Gan to Kagaku Ryoho. Cancer and ChemoTherapy 17(1): 89-95
1990
ISSN/ISBN: 0385-0684 PMID: 1688701 Document Number: 352026
Miniaturized improved nucleic acid precursor incorporation assay (MINI assay) has been developed by Kern D. H. and Tanigawa N. et al since 1985. We investigated in vitro effects of mitomycin C (MMC), cisplatin (CDDP) and bleomycin (BLM) against A 549 lung cancer cells and HeLa cells by MINI assay. 3H-thymidine (3H-TdR) uptake in the positive control was 734.2 cpm +/- 10 cpm. The cut-off level for in vitro sensitivity was defined as more than 80% inhibition of 3H-TdR uptake in the drug treated cells compared to the positive controls. A 549 cells were sensitive to MMC (81.6%), CDDP (78.6%), but not to BLM (-57%). HeLa cells were sensitive to MMC (91%), CDDP (79.4%), but not to BLM (43%). MINI assay could be done with fewer cells than other methods and the results were obtained within 5 days. This method was considered to be useful for the chemosensitivity test with human tumors.